.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, individuals along with metastatic stomach growths that acquired biomarker-matched treatments based on distributing cyst DNA profiling revealed a greater scientific advantage than those acquiring unparalleled therapy.